1-(3-chlorophenyl)-4-[3-[5-ethyl-4-(2-phenoxyethyl)-3H-1,2,4-triazol-2-yl]propyl]piperazine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 1-(3-chlorophenyl)-4-[3-[5-ethyl-4-(2-phenoxyethyl)-3H-1,2,4-triazol-2-yl]propyl]piperazine
• 化学式: C₂₅H₃₄ClN₅O
• 分子量: 456.0
• InChiKey: UWDORRPFDVRODA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  32
• 可旋转键数：
  10
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  34.6
• 氢给体数：
  0
• 氢受体数：
  5

文献信息

• TREATMENTS FOR DEPRESSION AND OTHER DISEASES WITH A LOW DOSE AGENT
  申请人：Pharmorx Therapeutics, Inc.

  公开号：EP2950799A2

  公开（公告）日：2015-12-09
• [EN] TREATMENTS FOR DEPRESSION AND OTHER DISEASES WITH A LOW DOSE AGENT<br/>[FR] TRAITEMENT DE LA DÉPRESSION ET AUTRES MALADIES AVEC UN AGENT À FAIBLE DOSE
  申请人：PHARMORX THERAPEUTICS INC

  公开号：WO2014120936A2

  公开（公告）日：2014-08-07

  The present invention relates to improved compositions and methods for the treatment or prevention of various diseases, including forms of depression, including, for example, breakthrough depression and treatment-refractory depression, and other mood disorders, as well as Parkinson's disease, bipolar disorder, bipolar disorder, attention deficit disorder (ADHD), Restless Leg Syndrome (RLS), and obesity. In some embodiments, the compositions and methods comprise low dose naltrexone or related opioid antagonists.